What is XERS's P/E ratio?

XERIS PHARMACEUTICALS INC (XERS) currently trades at a P/E ratio of 104.31.

XERIS PHARMACEUTICALS INC reports a Return on Equity (ROE) of 92.29%.

What is XERS's dividend yield?

XERIS PHARMACEUTICALS INC offers a dividend yield of 0.00%.

What is XERS's Quality Score?

Our AI rates XERS's overall financial quality at 69 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy XERS?

Our AI Timing Score for XERS is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does XERS belong to?

XERIS PHARMACEUTICALS INC is classified under the Healthcare >> Drug Manufacturers - Specialty & Generic sector on the NASDAQ exchange

XERS (NASDAQ) Stock Analysis | XERIS PHARMACEUTICALS INC

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

XERS AI Analysis Summary

Our AI summary for XERS: XERIS PHARMACEUTICALS INC (NASDAQ), Healthcare >> Drug Manufacturers - Specialty & Generic sector. The stock currently trades at a P/E of 104.31, ROE of 92.29%, a dividend yield of 0.00%. Its financial Quality Score stands at 69/100 — mid-range fundamentals relative to the market. The AI Timing Score is 91/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

XERS

XERIS PHARMACEUTICALS INC

USD 8.08

-0.34 (-4.04%) Day Change

Watchlist Portfolio Compare Chart

104.31

P/E

17.48

D/E

92.3%

ROE

3.1%

ROA

0.00%

Div Yield

-2.04

PEG

XERIS PHARMACEUTICALS INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 8.08 Price -0.34 (-4.04%) Day Change	NEWS SCORE: 94

XERS, the overall quality is ok ( Quality = 69) and the timing to buy is ...(Sign In to See)...

Loading chart...

69 QUALITY

Signal: NEUTRAL

Signal Description: Company financial health is OK

Reason: P/E ratio is relatively high
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Net profit margin is relatively low.
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not quite good , financial health is not good , and ability to make profit is not quite good , ...

Quality Factors

58%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	94
Magic Formula Rank by ROA	3103
Magic Formula Rank by ROE	3103
Magic Formula Rank by ROIC	3102
Price	8.08
PBV / Sector	111.72 / 3.22
Earning Per Share	0.07

PE / Sector	104.31 / 29.79
PEG or PE/Growth / Sector	-2.04 / 0.13
Average 1M Daily Value	14.05 M GREAT
Average 1W Daily Value	8.90 M

Timing Factors

42%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

41%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

58%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	3.81 / 15.21
NPM Average (%) / Sector	-29.37 / -10.83
NPM Change Average (%) / Sector	430.94 / 117.42 GREAT
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	3.06 / 8.15
ROA Average (%) / Sector	-12.11 / 2.87
ROA Change Average (%) / Sector	469.48 / 112.70 GREAT
ROE (%) / Sector	92.29 / -1.02 GREAT
ROE Average (%) / Sector	197.99 / 8.35 GREAT
ROE Change Average (%) / Sector	366.16 / 385.91 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.51
Dividend Average (%) / Sector	N/A / 3.06
Dividend Change Average (%) / Sector	N/A / 13.64

Registration Details

Analyze Date	2026-08-01 08:00:43
Symbol	XERS
Name	XERIS PHARMACEUTICALS INC
Sector	Healthcare >> Drug Manufacturers - Specialty & Generic
Market	NASDAQ
Listed Shares	172.64 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	1,453.65 / 10,754.62

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 1375 West Fulton Street, Chicago, IL, United States, 60607

Phone: 844 445 5704

Website: https://www.xerispharma.com

Employees: 435

Sector: Healthcare >> Drug Manufacturers - Specialty & Generic

Description: Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.